Part of GSK Plc, GlaxoSmithKline Intellectual Property Development Ltd. is a British company located in Middlesex that functions as an investment holding company. It was founded in 2012.\nThe company says this about itself: The Company is a member of the GlaxoSmithKline Group (the \"Group\"). The Company's principal activities are the development, enhancement, maintenance, protection and exploitation of intellectual property assets owned by the Company which may include but are not limited to, licensing out intellectual property rights relating to pharmaceutical products to the GlaxoSmithKline Group of companies (the \"Group\") and carrying out research and development activities.

Cancer Research Ventures Ltd. engages in the business of research and experimental development on biotechnology. It provides medical products. The company is headquartered in London, the United Kingdom.

Dr. Falk Pharma GmbH engages in the development and sale of medication for indications in hematology and gastroenterology in Germany and internationally. The company principally offers prescription drugs that are used in treating inflammatory bowel diseases, cholestatic liver diseases, irritable bowel syndromes, and constipation, as well as for colon cleansing prior to colonoscopies. It also organizes and sponsors medical education events; and offers publications for healthcare professionals, as well as for patients and their families. The company was formerly known as Dr. Falk Arzneimittel GmbH & Co KG and changed its name to Dr. Falk Pharma GmbH in 1989. Dr. Falk Pharma GmbH was founded in 1960 and is headquartered in Freiburg, Germany

Tonglian Group is a large-scale private enterprise group that spans the regional, multi-industry industries of energy, chemical, agricultural product processing, real estate, hotels and other industries, with the research.

Infectious Disease Research Institute operates as a innovative science to research and development company. It offers pipeline, adjuvants, vaccines, diagnostics and drugs products. The firm also provides manufacturing, analytical methods, stability studies, process and contact services. The company was founded by Steven G. Reed in 1993 and is headquartered in Seattle, WA.

Jinan Kangquan Pharmaceutical Technology Co., Ltd., established on 2005-04-14, Business scope includes licensed business items:none;General operating items:Development of medical technology,transfer,technical consulting.(Except for projects that have not obtained special permits)

Genome Pharmaceuticals Institute Co. Ltd. is a

Sequella, Inc. develops antibiotic drugs resistant to bacterial, fungal, and parasitic infections. It offers product for Mycobacterium tuberculosis, Helicobacter pylori, Clostridium difficile, Nontuberculous mycobacteria, Trypanosomes, and fungal infections. The company was founded by Carol A. Nacy and Leo Einck in 1997 and is headquartered in Rockville, MD.

National Institute of Pharmaceutical Education & Research (doing business as NIPER) is an Indian company located in Sahibzada Ajit Singh Nagar and ultimately controlled by the Government of India that provides research services in pharmaceutical sciences. It was founded in 1998.

Part of Abbott Laboratories, Hokuriku Seiyaku Co., Ltd. is a Japanese company located in Katsuyama. The firm develops, manufactures, and sells pharmaceuticals. On June 30, 2002 Abbott Laboratories acquired Hokuriku Seiyaku Co., Ltd. for $291.31 million.

Shanghai Tonglian Pharmaceutical Co., Ltd., established on 2007-09-13, Business scope includes licensed projects:pharmaceutical production;Technology Import and Export;Import and export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:technology development,technology transfer,technical consulting,Technical Services,Technology Exchange,Technology Promotion;Conference and Exhibition Services,marketing planning.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.